Effect of indomethacin on glomerular permeability in the nephrotic syndrome.
Effect of indomethacin on glomerular permeability in the nephrotic syndrome.
复制标题
吲哚美辛对肾病综合征肾小球通透性的影响。
DOI：
10.1038/ki.1979.133
复制
发表时间：
1979
影响因子：
19.6
通讯作者：
P. Wijdeveld
中科院分区：
文献类型：
--
作者：
R. G. Tiggeler;B. Hulme;P. Wijdeveld
在1966年，Mülelsen和Lambert [1]介绍了非类固醇激素药物吲哚美辛治疗肾小球肾炎，并证明该药物可以减少肾病综合征患者的蛋白尿。据报道，氨基安替比林和保泰松[2-4]以及随后的羟保泰松[5]对蛋白尿有类似的影响。虽然这些观察结果已经由Meselsen等人[6-9]和其他人[10-17]详细阐述，但该效应迄今仍无法解释。
In 1966, Michielsen and Lambert [1] introduced the nonsteroid antiinflammatory drug indomethacin in the treatment of glomerulonephritis and demonstrated that the drug can reduce proteinuria in patients with the nephrotic syndrome. Similar effects on proteinuria had been reported for amino-phenazone and phenylbutazone [2–4] and, subsequently, oxyphenbutazone [5]. Although these observations have been elaborated in detail by Michielsen et al [6–9] and others [10–17], the effect has so far remained unexplained.